| 7,160,681 |
Method for regulating cell growth and assays related thereto |
| 7,090,865 |
Composition and method for treating autoimmune hemolytic anemia |
| 6,974,677 |
Human MEKK proteins, corresponding nucleic acid molecules, and uses therefor |
| 6,951,733 |
Method for testing drug susceptibility of Mycobacterium tuberculosis |
| 6,916,799 |
Substituted Porphyrins |
| 6,875,749 |
Methods for facilitating vascular growth |
| 6,737,398 |
Modulation of gamma delta T cells to regulate airway hyperresponsiveness |
| 6,693,086 |
Systemic immune activation method using nucleic acid-lipid complexes |
| 6,579,694 |
Agar medium for the growth of Mycobacterium tuberculosis |
| 6,576,433 |
Method for identification of cell growth or differentiation factors |
| 6,555,318 |
Method for identification of cell growth or differentiation factors |
| 6,544,975 |
Substituted porphyrins |
| 6,503,509 |
Method for receptor desensitization |
| 6,500,430 |
Product and process to regulate actin polymerization in T lymphocytes |
| 6,497,840 |
Ultraviolet germicidal system |
| 6,495,331 |
Regulation of cytokine production in a hematopoietic cell |
| 6,479,477 |
Substituted porphyrins |
| 6,475,987 |
Tall-1 receptor homologues |
| 6,399,607 |
Aminomethylene amide analogs of pyrazinamide with intracellular antimycobacterial activity against pyrazinamide-resistant mycobacteria combined with a rifamycin |
| 6,333,170 |
Method and product for regulating cell responsiveness to external signals |
| 6,312,934 |
Human MEKK proteins, corresponding nucleic acid molecules, and uses therefor |
| 6,306,612 |
Methods of facilitating vascular growth |
| 6,264,950 |
Product and process for T lymphocyte immunosuppression |
| 6,264,888 |
Ultraviolet germicidal apparatus and method |
| 6,248,723 |
Method for treatment of inflammatory disease |
| 6,231,894 |
Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase |
| 6,187,584 |
Products and processes for regulation of gene recombination |
| 6,156,503 |
Diagnosing asthma patients predisposed to adverse .beta.-agonist reactions |
| 6,132,978 |
Method to regulate CD40 signaling |
| 6,110,739 |
Method to produce novel embryonic cell populations |
| 6,074,861 |
MEKK proteins |
| 6,060,054 |
Product for T lymphocyte immunosuppression |
| 6,040,152 |
Method and assay for regulation of T cell proliferation |
| 5,985,261 |
Use of thioredoxin-like molecules for induction of MnSOD to treat oxidative damage |
| 5,981,265 |
Methods for regulating MEKK protein activity |
| 5,976,819 |
Product and process to regulate actin polymerization in T lymphocytes |
| 5,976,786 |
Screening methods for the identification of compounds that modulate apoptosis in immunodeficiency virus infected cells |
| 5,959,074 |
Products and processes for regulation of gene recombination |
| 5,935,568 |
Gene therapy for effector cell regulation |
| 5,914,268 |
Embryonic cell populations and methods to isolate such populations |
| 5,910,417 |
Regulation of cytokine production in a hematopoietic cell |
| 5,908,620 |
Treatment for diseases involving inflammation |
| 5,906,815 |
Treatment for diseases involving inflammation |
| 5,874,301 |
Embryonic cell populations and methods to isolate such populations |
| 5,854,043 |
MEKK-related signal transduction kinases |
| 5,851,786 |
Product and process to regulate actin polymerization |
| 5,820,866 |
Product and process for T cell regulation |
| 5,753,446 |
Mitogen ERK kinase kinase (MEKK) assay |
| 5,705,151 |
Gene therapy for T cell regulation |
| 5,698,679 |
Product and process for targeting an immune response |
| 5,674,483 |
Treatment for diseases involving inflammation |
| 5,567,590 |
Methods of diagnosing steroid-resistant inflammation due to type I or type II nuclear glucocorticoid receptor binding abnormalities |
| 5,470,835 |
Transfer factor and methods of use |
| 5,405,941 |
MEKK protein, capable of phosphorylating MEK |
